GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longeveron Inc (NAS:LGVN) » Definitions » Gross Profit

Longeveron (Longeveron) Gross Profit : $0.47 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Longeveron Gross Profit?

Longeveron's gross profit for the three months ended in Mar. 2024 was $0.33 Mil. Longeveron's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $0.47 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Longeveron's gross profit for the three months ended in Mar. 2024 was $0.33 Mil. Longeveron's Revenue for the three months ended in Mar. 2024 was $0.55 Mil. Therefore, Longeveron's Gross Margin % for the quarter that ended in Mar. 2024 was 60.04%.

Longeveron had a gross margin of 60.04% for the quarter that ended in Mar. 2024 => Durable competitive advantage

During the past 6 years, the highest Gross Margin % of Longeveron was 48.47%. The lowest was 31.17%. And the median was 32.44%.


Longeveron Gross Profit Historical Data

The historical data trend for Longeveron's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longeveron Gross Profit Chart

Longeveron Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial 1.83 1.83 0.59 0.50 0.22

Longeveron Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.09 0.05 - 0.33

Competitive Comparison of Longeveron's Gross Profit

For the Biotechnology subindustry, Longeveron's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Longeveron's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longeveron's Gross Profit distribution charts can be found below:

* The bar in red indicates where Longeveron's Gross Profit falls into.



Longeveron Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Longeveron's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=0.709 - 0.488
=0.22

Longeveron's Gross Profit for the quarter that ended in Mar. 2024 is calculated as

Gross Profit (Q: Mar. 2024 )=Revenue - Cost of Goods Sold
=0.548 - 0.219
=0.33

Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.47 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Longeveron's Gross Margin % for the quarter that ended in Mar. 2024 is calculated as

Gross Margin % (Q: Mar. 2024 )=Gross Profit (Q: Mar. 2024 ) / Revenue (Q: Mar. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.33 / 0.548
=60.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Longeveron  (NAS:LGVN) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Longeveron had a gross margin of 60.04% for the quarter that ended in Mar. 2024 => Durable competitive advantage


Longeveron Gross Profit Related Terms

Thank you for viewing the detailed overview of Longeveron's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Longeveron (Longeveron) Business Description

Traded in Other Exchanges
N/A
Address
1951 NW 7th Avenue, Suite 520, Miami, FL, USA, 33136
Longeveron Inc is a clinical-stage biotechnology company developing cellular therapies for specific aging-related and life-threatening conditions. The Company operates out of its leased facilities in Miami, Florida. The company has generated revenue from three sources: 1) Grant awards. 2) The Bahamas Registry Trial. 3) Contract development and manufacturing services.
Executives
Cathy Ross director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Khoso Baluch director 1430 US HIGHWAY 206, SUITE 200, BEDMINSTER NJ 07921
Jeffrey Pfeffer director
Lisa Locklear officer: Chief Financial Officer 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Nataliya Agafonova officer: Chief Medical Officer 1951 NW 7TH AVENUE, MIAMI FL 33136
James Clavijo officer: CFO and Treasurer 1691 MICHIGAN AVE SUITE 435, MIAMI FL 33139
Hashad Mohamed Wa'el Ahmed officer: Chief Executive Officer SUITE 520, 1951 NW 7TH AVE., MIAMI FL 33136
Joshua Hare director, officer: Chief Scientific Officer C/O 470 NAUTILUS STREET, SUITE 300, LA JOLLA CA 92073
Rock Soffer director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Kwan-hong Christopher Min officer: Chief Medical Officer 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Todd C Girolamo director 110 ALLEN ROAD, 2ND FLOOR, BASKING RIDGE NJ 07920
Geoff Green officer: CEO 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Paul T Lehr officer: General Counsel, Secretary 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Ursula Ungaro director 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136
Donald M Soffer director, 10 percent owner 1951 NW 7TH AVENUE, SUITE 520, MIAMI FL 33136